



## Clinical trial results:

### A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Assess The Efficacy, Long-Term Safety And Tolerability Of PF-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

#### Summary

EudraCT number	2013-002643-28
Trial protocol	LT GB ES HU
Global end of trial date	05 July 2016

#### Results information

Result version number	v1
This version publication date	08 July 2017
First version publication date	08 July 2017

#### Trial information

##### Trial identification

Sponsor protocol code	B1481020
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01968967
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Pfizer
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	ClinicalTrials.gov Call Center, Pfizer, 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	ClinicalTrials.gov Call Center, Pfizer, 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 April 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	05 July 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate a superior low-density lipoprotein cholesterol (LDL-C) lowering effect of Bococizumab 150 milligram (mg) administered by the subcutaneous (SC) route every 14 days (Q14D) compared to placebo, in subjects with primary hyperlipidemia or mixed dyslipidemia at high and very high risk for cardiovascular events receiving a maximally tolerated dose of statin therapy.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials subjects were followed

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 October 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 55
Country: Number of subjects enrolled	Colombia: 53
Country: Number of subjects enrolled	Hungary: 70
Country: Number of subjects enrolled	Lithuania: 19
Country: Number of subjects enrolled	Mexico: 69
Country: Number of subjects enrolled	Romania: 57
Country: Number of subjects enrolled	Russian Federation: 30
Country: Number of subjects enrolled	Spain: 80
Country: Number of subjects enrolled	Taiwan: 14
Country: Number of subjects enrolled	United Kingdom: 185
Country: Number of subjects enrolled	United States: 1475
Country: Number of subjects enrolled	France: 32
Worldwide total number of subjects	2139
EEA total number of subjects	443

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1250
From 65 to 84 years	875
85 years and over	14

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

This study was conducted from 29 October 2013 to 05 July 2016 at multiple sites.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Carer, Assessor, Subject

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Subjects received placebo matched to Bococizumab (PF--04950615) subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to 58 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once every 2 weeks over a period of 52 weeks.

<b>Arm title</b>	Bococizumab (PF--04950615) 150 mg
------------------	-----------------------------------

Arm description:

Subjects received Bococizumab (PF--04950615) 150 mg subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to 58 weeks.

Arm type	Experimental
Investigational medicinal product name	PF-04950615
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received Bococizumab (PF-04950615) 150 mg subcutaneous injection once every 2 weeks over a period of 52 weeks.

<b>Number of subjects in period 1</b>	Placebo	Bococizumab (PF--04950615) 150 mg
Started	1071	1068
Treated	1065	1063
Completed	925	934
Not completed	146	134
Consent withdrawn by subject	71	61
Did Not Meet Entrance Criteria	2	3
Death	9	2
Adverse event	9	8
Randomized Not Treated	6	5
Unspecified	22	22
Lost to follow-up	26	31
Protocol deviation	1	2

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description:	
Subjects received placebo matched to Bococizumab (PF--04950615) subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to 58 weeks.	
Reporting group title	Bococizumab (PF--04950615) 150 mg
Reporting group description:	
Subjects received Bococizumab (PF--04950615) 150 mg subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to 58 weeks.	

Reporting group values	Placebo	Bococizumab (PF--04950615) 150 mg	Total
Number of subjects	1071	1068	2139
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	618	632	1250
From 65-84 years	443	432	875
85 years and over	10	4	14
Age Continuous Units: years			
arithmetic mean	62.2	61.8	
standard deviation	± 9.8	± 9.3	-
Gender, Male/Female Units: Subjects			
Female	434	434	868
Male	637	634	1271

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Subjects received placebo matched to Bococizumab (PF--04950615) subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to 58 weeks.	
Reporting group title	Bococizumab (PF--04950615) 150 mg
Reporting group description:	
Subjects received Bococizumab (PF--04950615) 150 mg subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to 58 weeks.	

### Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12

End point title	Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
End point description:	
Full analysis set (FAS) included all subjects who were randomized. Here, "Number of subjects analyzed (N)" signifies number of subjects who were evaluable for this outcome measure.	
End point type	Primary
End point timeframe:	
Baseline, Week 12	

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	994	980		
Units: percent change				
arithmetic mean (standard deviation)	1 ( $\pm$ 22.55)	-54.9 ( $\pm$ 26.84)		

### Statistical analyses

Statistical analysis title	PF--04950615 150 mg Versus (vs) Placebo
Statistical analysis description:	
Least square (LS) mean difference and associated 95 percent (%) confidence interval (CI), and p-value were derived from mixed effect model repeat measurement (MMRM) model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	1974
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-56.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-58.3
upper limit	-54
Variability estimate	Standard error of the mean
Dispersion value	1.1

### Secondary: Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12, 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =997, 981)	-0.1 (± 16.18)	-34.9 (± 18.34)		
Week 24 (n =988, 988)	1 (± 18.68)	-30.5 (± 21.56)		
Week 52 (n =920, 932)	-0.3 (± 18.75)	-25.3 (± 23.43)		

### Statistical analyses

Statistical analysis title	PF--04950615 150 mg vs Placebo
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline	



value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-36.5
upper limit	-33.5
Variability estimate	Standard error of the mean
Dispersion value	0.76

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
-----------------------------------	--------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-24.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.6
upper limit	-22.8
Variability estimate	Standard error of the mean
Dispersion value	0.96

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
-----------------------------------	--------------------------------

Statistical analysis description:

Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
-------------------	---

Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-31.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.3
upper limit	-29.8
Variability estimate	Standard error of the mean
Dispersion value	0.89

### Secondary: Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12, 24 and 52
End point description: FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe: Baseline, Week 12, 24, 52	

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =994, 978)	0.4 (± 18.83)	-50.4 (± 27.42)		
Week 24 (n =987, 988)	1.5 (± 21.43)	-44.9 (± 31.17)		
Week 52 (n =915, 929)	-0.4 (± 21.78)	-37.4 (± 32.92)		

### Statistical analyses

Statistical analysis title	PF--04950615 150 mg vs Placebo
Statistical analysis description: Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-50.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-52.9
upper limit	-48.8
Variability estimate	Standard error of the mean
Dispersion value	1.04

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-36.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-38.6
upper limit	-33.6
Variability estimate	Standard error of the mean
Dispersion value	1.28

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-46.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-48.5
upper limit	-43.8
Variability estimate	Standard error of the mean
Dispersion value	1.19

### Secondary: Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (non HDL-C) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (non HDL-C) at Week 12, 24 and 52
End point description:	FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.
End point type	Secondary
End point timeframe:	Baseline, Week 12, 24, 52

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =996, 980)	0.2 (± 21.22)	-49.7 (± 25.51)		
Week 24 (n =987, 987)	1.6 (± 24.65)	-43.8 (± 30.02)		
Week 52 (n =919, 932)	-0.3 (± 24.62)	-36.8 (± 32.73)		

### Statistical analyses

Statistical analysis title	PF--04950615 150 mg vs Placebo
Statistical analysis description:	Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-50.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-52.1
upper limit	-48
Variability estimate	Standard error of the mean
Dispersion value	1.04

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-45.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-47.9
upper limit	-43.1
Variability estimate	Standard error of the mean
Dispersion value	1.22

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-35.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-38.5
upper limit	-33.3
Variability estimate	Standard error of the mean
Dispersion value	1.33

**Secondary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides (TG) Cut-off of Less Than (<) 200 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides (TG) Cut-off of Less Than (<) 200 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52
-----------------	--

End point description:

A subset of FAS included all subjects who were randomized and had TG <200 mg/dL at pre-randomization. Here, "n" signifies number of subjects evaluable at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	791	788		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =734, 725)	1.9 (± 23.07)	-55.6 (± 26.81)		
Week 24 (n =730, 729)	3.9 (± 27.17)	-49.2 (± 32.58)		
Week 52 (n =683, 688)	3.2 (± 26.65)	-40.6 (± 36.45)		

**Statistical analyses**

Statistical analysis title	PF--04950615 150 mg vs Placebo
----------------------------	--------------------------------

Statistical analysis description:

Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline

value\*visit interaction and geographical region. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	1579
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-57.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-60.2
upper limit	-55.2
Variability estimate	Standard error of the mean
Dispersion value	1.29

---

**Statistical analysis title**

PF--04950615 150 mg vs Placebo

Statistical analysis description:

Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	1579
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-53.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-56.1
upper limit	-50
Variability estimate	Standard error of the mean
Dispersion value	1.55

---

**Statistical analysis title**

PF--04950615 150 mg vs Placebo

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
-------------------	---

Number of subjects included in analysis	1579
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-42.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-46.2
upper limit	-39.5
Variability estimate	Standard error of the mean
Dispersion value	1.7

**Secondary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to ( $\geq$ ) 200 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to ( $\geq$ ) 200 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52
-----------------	---

End point description:

A subset of FAS included all subjects who were randomized and had TG  $\geq$ 200 mg/dL at pre-randomization. Here, "n" signifies number of subjects evaluable at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	280	280		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =260, 255)	-1.5 ( $\pm$ 20.82)	-53 ( $\pm$ 26.9)		
Week 24 (n =257, 260)	1.1 ( $\pm$ 28.21)	-42.8 ( $\pm$ 31.87)		
Week 52 (n =237, 241)	-1.2 ( $\pm$ 27.78)	-36.3 ( $\pm$ 34.88)		

**Statistical analyses**

Statistical analysis title	PF--04950615 150 mg vs Placebo
----------------------------	--------------------------------

Statistical analysis description:

Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline



value\*visit interaction and geographical region. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	560
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-51.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-55.9
upper limit	-47.7
Variability estimate	Standard error of the mean
Dispersion value	2.09

---

**Statistical analysis title**

PF--04950615 150 mg vs Placebo

Statistical analysis description:

Week 24: LS mean difference and associated 95% CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	560
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-44
Confidence interval	
level	95 %
sides	2-sided
lower limit	-49.1
upper limit	-38.8
Variability estimate	Standard error of the mean
Dispersion value	2.61

---

**Statistical analysis title**

PF--04950615 150 mg vs Placebo

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
-------------------	---

Number of subjects included in analysis	560
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-34.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-40.2
upper limit	-29
Variability estimate	Standard error of the mean
Dispersion value	2.83

## Secondary: Percent Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Week 12, 24 and 52
End point description:	FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.
End point type	Secondary
End point timeframe:	Baseline, Week 12, 24, 52

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =994, 975)	2.4 (± 85.08)	-26.3 (± 42.63)		
Week 24 (n =984, 983)	8.7 (± 146)	-22.7 (± 51.48)		
Week 52 (n =918, 927)	4.3 (± 139.49)	-20.9 (± 110.14)		

## Statistical analyses

Statistical analysis title	PF--04950615 150 mg vs Placebo
Statistical analysis description:	Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-28.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-34.4
upper limit	-22.5
Variability estimate	Standard error of the mean
Dispersion value	3.04

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-31.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-40.6
upper limit	-21.5
Variability estimate	Standard error of the mean
Dispersion value	4.86

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-25.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-36.8
upper limit	-13.7
Variability estimate	Standard error of the mean
Dispersion value	5.89

### Secondary: Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52
End point description:	FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.
End point type	Secondary
End point timeframe:	Baseline, Week 12, 24, 52

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =996, 981)	0.4 (± 13.92)	6.2 (± 14.99)		
Week 24 (n =987, 987)	0.5 (± 15.25)	6.1 (± 15.32)		
Week 52 (n =919, 932)	1.2 (± 16.09)	6.5 (± 17.87)		

### Statistical analyses

Statistical analysis title	PF--04950615 150 mg vs Placebo
Statistical analysis description:	Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.5
upper limit	7
Variability estimate	Standard error of the mean
Dispersion value	0.63

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
-----------------------------------	--------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.7
upper limit	6.7
Variability estimate	Standard error of the mean
Dispersion value	0.76

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
-----------------------------------	--------------------------------

Statistical analysis description:

Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
-------------------	---

Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	5.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.2
upper limit	6.8
Variability estimate	Standard error of the mean
Dispersion value	0.67

## Secondary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52

End point title	Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52
End point description:	FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.
End point type	Secondary
End point timeframe:	Baseline, Week 24, 52

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percent change				
arithmetic mean (standard deviation)				
Week 24 (n =987, 989)	3.2 (± 27.45)	-47.5 (± 32.5)		
Week 52 (n =920, 929)	2.1 (± 27)	-39.5 (± 36.08)		

## Statistical analyses

Statistical analysis title	PF--04950615 150 mg vs Placebo
Statistical analysis description:	Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-50.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-53.3
upper limit	-48
Variability estimate	Standard error of the mean
Dispersion value	1.34

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
-----------------------------------	--------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-40.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-43.5
upper limit	-37.8
Variability estimate	Standard error of the mean
Dispersion value	1.46

### **Secondary: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12, 24 and 52
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =997, 981)	3.5 (± 38.25)	-12.9 (± 39.99)		
Week 24 (n =988, 988)	5.1 (± 51.06)	-11.5 (± 41.33)		
Week 52 (n =920, 932)	0.3 (± 43.63)	-12.5 (± 40.82)		

## Statistical analyses

Statistical analysis title	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-16.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20
upper limit	-13.2
Variability estimate	Standard error of the mean
Dispersion value	1.73

Statistical analysis title	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg



Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-12.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.5
upper limit	-9
Variability estimate	Standard error of the mean
Dispersion value	1.91

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
-----------------------------------	-------------------------------

Statistical analysis description:

Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-16.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.7
upper limit	-12.6
Variability estimate	Standard error of the mean
Dispersion value	2.05

### **Secondary: Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52
-----------------	---

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =995, 980)	-0.6 (± 11.22)	2.8 (± 11.73)		
Week 24 (n =987, 988)	-0.9 (± 12.1)	2.7 (± 11.93)		
Week 52 (n =916, 929)	-1.2 (± 12.34)	2.6 (± 13.75)		

## Statistical analyses

Statistical analysis title	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	3.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.4
upper limit	4.3
Variability estimate	Standard error of the mean
Dispersion value	0.49

Statistical analysis title	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	3.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	2.7
upper limit	4.9
Variability estimate	Standard error of the mean
Dispersion value	0.57

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
-----------------------------------	-------------------------------

Statistical analysis description:

Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.5
upper limit	4.5
Variability estimate	Standard error of the mean
Dispersion value	0.51

### **Secondary: Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52
-----------------	---

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =993, 972)	-1.2 (± 13.05)	-1 (± 13.75)		
Week 24 (n =986, 986)	-0.9 (± 13.56)	0.1 (± 14.28)		
Week 52 (n =916, 928)	-2.5 (± 13.5)	-1 (± 13.72)		

## Statistical analyses

Statistical analysis title	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	1.4
Variability estimate	Standard error of the mean
Dispersion value	0.59

Statistical analysis title	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	1.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	2.7
Variability estimate	Standard error of the mean
Dispersion value	0.61

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
-----------------------------------	-------------------------------

Statistical analysis description:

Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	2.3
Variability estimate	Standard error of the mean
Dispersion value	0.61

### **Secondary: Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52
-----------------	---

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =997, 981)	3.5 (± 38.25)	-12.9 (± 39.99)		
Week 24 (n =988, 988)	5.1 (± 51.06)	-11.5 (± 41.33)		
Week 52 (n =920, 932)	0.3 (± 43.63)	-12.5 (± 40.82)		

## Statistical analyses

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-16.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20
upper limit	-13.2
Variability estimate	Standard error of the mean
Dispersion value	1.73

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-12.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.5
upper limit	-9
Variability estimate	Standard error of the mean
Dispersion value	1.91

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
-----------------------------------	-------------------------------

Statistical analysis description:

Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-16.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.7
upper limit	-12.6
Variability estimate	Standard error of the mean
Dispersion value	2.05

**Secondary: Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (<) 200 Milligram per Deciliter (mg/dL) at Week 12**

End point title	Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (<) 200 Milligram per Deciliter (mg/dL) at Week 12
-----------------	---

End point description:

A subset of FAS included all subjects who were randomized and had TG <200 mg/dL at pre-randomization. Here, "n" signifies number of subjects evaluable at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	791	788		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =791, 787)	109.1 (± 33.24)	107.1 (± 30.43)		
Change at Week 12 (n =734, 725)	0.3 (± 25.7)	-59.3 (± 32.3)		

## Statistical analyses

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	1579
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-60.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-63.1
upper limit	-57.6
Variability estimate	Standard error of the mean
Dispersion value	1.4

## Secondary: Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (≥) 200 Milligram per Deciliter (mg/dL) at Week 12

End point title	Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (≥) 200 Milligram per Deciliter (mg/dL) at Week 12
End point description:	
A subset of FAS included all subjects who were randomized and had TG ≥200 mg/dL at pre-randomization. Here, "n" signifies number of subjects evaluable at specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12	



<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	280	280		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =280, 280)	125.9 (± 40.08)	121.5 (± 37.84)		
Change at Week 12 (n =260, 255)	-3.4 (± 29.08)	-64.8 (± 38.94)		

## Statistical analyses

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	560
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-62.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-68.3
upper limit	-57.3
Variability estimate	Standard error of the mean
Dispersion value	2.8

## Secondary: Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12

End point title	Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12	

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =1071, 1067)	113.5 (± 35.9)	110.9 (± 33.13)		
Change at Week 12 (n =994, 980)	-0.7 (± 26.66)	-60.7 (± 34.22)		

## Statistical analyses

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
Statistical analysis description:	
LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-61
Confidence interval	
level	95 %
sides	2-sided
lower limit	-63.5
upper limit	-58.5
Variability estimate	Standard error of the mean
Dispersion value	1.27

## Secondary: Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12

End point title	Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12	

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =1071, 1067)	186.3 (± 40.77)	183.1 (± 38.31)		
Change at Week 12 (n =997, 981)	-1.8 (± 31.62)	-64.5 (± 38.01)		

## Statistical analyses

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-63.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-66.6
upper limit	-60.9
Variability estimate	Standard error of the mean
Dispersion value	1.46

## Secondary: Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (HDL-C) at Week 12

End point title	Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (HDL-C) at Week 12
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12	

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =1071, 1066)	138 (± 39.67)	135.3 (± 36.85)		
Change at Week 12 (n =996, 980)	-1.6 (± 30.93)	-67 (± 38.89)		

## Statistical analyses

<b>Statistical analysis title</b>	PF--04950615 150 mg vs Placebo
Statistical analysis description:	
LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-66.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-69.3
upper limit	-63.6
Variability estimate	Standard error of the mean
Dispersion value	1.46

## Secondary: Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12

End point title	Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12	

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =1070, 1067)	94 (± 24.26)	92.3 (± 22.74)		
Change at Week 12 (n =994, 978)	-0.7 (± 18.35)	-46 (± 26.58)		

## Statistical analyses

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-45.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-47.7
upper limit	-43.9
Variability estimate	Standard error of the mean
Dispersion value	0.97

## Secondary: Absolute Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Week 12

End point title	Absolute Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Week 12
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12	

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =1069, 1063)	45.3 (± 49.77)	46.4 (± 55.57)		
Change at Week 12 (n =994, 975)	0 (± 12.07)	-10.6 (± 18.36)		

## Statistical analyses

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-10.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.8
upper limit	-9.3
Variability estimate	Standard error of the mean
Dispersion value	0.63

## Secondary: Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12

End point title	Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12	

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =1071, 1066)	48.3 (± 12.42)	47.8 (± 12.72)		
Change at Week 12 (n =996, 981)	-0.1 (± 6.84)	2.5 (± 7.07)		

## Statistical analyses

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.1
upper limit	3.3
Variability estimate	Standard error of the mean
Dispersion value	0.31

## Secondary: Absolute Change From Baseline in Ratio of Fasting Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52

End point title	Absolute Change From Baseline in Ratio of Fasting Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: Ratio				
arithmetic mean (standard deviation)				
Baseline (n =1071, 1066)	4.1 (± 1.22)	4 (± 1.19)		
Change at Week 12 (n =996, 980)	0 (± 0.86)	-1.5 (± 1.09)		
Change at Week 24 (n =987, 987)	0 (± 0.96)	-1.4 (± 1.15)		
Change at Week 52 (n =919, 932)	0 (± 0.97)	-1.1 (± 1.21)		

## Statistical analyses

Statistical analysis title	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	-1.5
Variability estimate	Standard error of the mean
Dispersion value	0.04

Statistical analysis title	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-1.4



Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	-1.3
Variability estimate	Standard error of the mean
Dispersion value	0.05

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
-----------------------------------	-------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	-1
Variability estimate	Standard error of the mean
Dispersion value	0.05

### **Secondary: Absolute Change From Baseline in Ratio of Fasting Apolipoprotein B (ApoB) to Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52**

End point title	Absolute Change From Baseline in Ratio of Fasting Apolipoprotein B (ApoB) to Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: Ratio				
arithmetic mean (standard deviation)				
Baseline (n =1070, 1067)	0.7 (± 0.21)	0.7 (± 0.2)		
Change at Week 12 (n =994, 978)	0 (± 0.14)	-0.3 (± 0.21)		
Change at Week 24 (n =987, 988)	0 (± 0.15)	-0.3 (± 0.23)		
Change at Week 52 (n =915, 929)	0 (± 0.16)	-0.2 (± 0.23)		

## Statistical analyses

Statistical analysis title	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 12: LS mean difference and associated 95% confidence interval CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	-0.3
Variability estimate	Standard error of the mean
Dispersion value	0.01

Statistical analysis title	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 24: LS mean difference and associated 95% confidence interval CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-0.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	-0.3
Variability estimate	Standard error of the mean
Dispersion value	0.01

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
-----------------------------------	-------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% confidence interval CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	-0.2
Variability estimate	Standard error of the mean
Dispersion value	0.01

**Secondary: Percentage of Subjects Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to ( $\leq$ ) 100 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52**

End point title	Percentage of Subjects Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to ( $\leq$ ) 100 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52
-----------------	---

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12, 24, 52

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percentage of subjects				
number (not applicable)				
Week 12 (n =994, 980)	45.3	90.9		
Week 24 (n =987, 990)	43.2	85.8		
Week 52 (n =920, 930)	45	79.8		

## Statistical analyses

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 12: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Odds ratio (OR)
Point estimate	27
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.21
upper limit	38.02

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description:	
Week 24: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Odds ratio (OR)
Point estimate	12.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.84
upper limit	16.86

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description: Week 52: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.	
Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Odds ratio (OR)
Point estimate	6.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.99
upper limit	8.06

**Secondary: Percentage of Subjects Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to ( $\leq$ ) 70 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52**

End point title	Percentage of Subjects Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to ( $\leq$ ) 70 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52
End point description: FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe: Week 12, 24, 52	

End point values	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1071	1068		
Units: percentage of subjects				
number (not applicable)				
Week 12 (n =994, 980)	5.9	78.6		
Week 24 (n =987, 990)	7.8	69.8		
Week 52 (n =920, 930)	6.8	61.4		

**Statistical analyses**

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
Statistical analysis description: Week 12: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects	

for treatment group, baseline value, geographical region and triglyceride subgroup.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Odds ratio (OR)
Point estimate	86.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	61.74
upper limit	121.25

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
-----------------------------------	-------------------------------

Statistical analysis description:

Week 52: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Odds ratio (OR)
Point estimate	25.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.9
upper limit	34.47

<b>Statistical analysis title</b>	PF-04950615 150 mg vs Placebo
-----------------------------------	-------------------------------

Statistical analysis description:

Week 24: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.

Comparison groups	Placebo v Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	2139
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Odds ratio (OR)
Point estimate	35.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	26.83
upper limit	47.96

**Secondary: Plasma Concentration of PF-04950615 at Week 12, 24 and 52**

End point title	Plasma Concentration of PF-04950615 at Week 12, 24 and
-----------------	--

## End point description:

Plasma concentration of PF-04950615 at Week 12, 24 and 52 was reported. Analysis set included subjects who received at least 1 dose of PF-04950615. Here, "n" signifies those subjects who were evaluable at specified time points.

End point type	Secondary
----------------	-----------

## End point timeframe:

Week 12, 24, 52

## Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint was planned to be analyzed only for reporting arm: Bococizumab (PF-04950615) 150 mg.

<b>End point values</b>	Bococizumab (PF-04950615) 150 mg			
Subject group type	Reporting group			
Number of subjects analysed	1063			
Units: Microgram per milliliter				
arithmetic mean (standard deviation)				
Week 12 (n= 996)	4.91 (± 4.987)			
Week 24 (n= 975)	4.74 (± 5.772)			
Week 52 (n= 915)	3.6 (± 4.685)			

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of Subjects With Adverse Events (AEs) Related to Type 1 or 3 Hypersensitivity Reactions and Injection Site Reactions**

End point title	Number of Subjects With Adverse Events (AEs) Related to Type 1 or 3 Hypersensitivity Reactions and Injection Site Reactions
-----------------	---

## End point description:

Type 1 hypersensitivity or allergic reactions were possible in response to any injected protein and included shortness of breath, urticaria, anaphylaxis and angioedema. Type 3 hypersensitivity reactions were similar to Type 1 hypersensitivity reactions but were likely to be delayed from the time of injection and included symptoms such as rash, urticaria, polyarthritis, myalgia's, polysynovitis, fever and if severe then included glomerulonephritis. Injection site reactions included injection site bruising, discolouration, erythema, haematoma, haemorrhage, nodule, induration, inflammation, mass, pain, paraesthesia, pruritus, swelling, vesicles, warmth, scab and rash. Subjects with type 1 or type 3 hypersensitivity reactions and subjects with injection site reactions were reported in this outcome measure. Safety analysis population. Here, "n" signifies those subjects who were evaluable at specified time points for each reporting arm respectively.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline up to end of study (up to Week 58)

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1065	1063		
Units: subjects				
Type 1 or 3 hypersensitivity reactions	2	2		
Injection site reactions	56	144		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb)

End point title	Percentage of Subjects With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb)
-----------------	--

End point description:

Percentage of subjects with at least 1 positive ADA titer or 1 positive nAb titer were reported. ADA titer  $\geq 6.23$  was considered to be ADA positive and nAb titer  $\geq 1.58$  was considered to be nAb positive. Safety analysis population included all subjects who received at least 1 dose of study treatment. Here, "N" signifies those subjects who were evaluable for this endpoint for each reporting arm respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to end of study (up to Week 58)

<b>End point values</b>	Placebo	Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	231	1046		
Units: Percentage of subjects				
number (not applicable)				
ADA	0.9	46.7		
nAb	0.4	30.3		

## Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to end of study (up to Week 58)

Adverse event reporting additional description:

Same event may appear as AE and serious AE, what is presented are distinct events. Event may be categorized as serious in 1 subject and nonserious in another subject or 1 subject may have experienced both serious and nonserious event during study. Safety analysis set included all subjects who received at least 1 dose of study drug.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo matched to Bococizumab (PF--04950615) subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to 58 weeks.

Reporting group title	PF--04950615 150 mg
-----------------------	---------------------

Reporting group description:

Subjects received Bococizumab (PF--04950615) 150 mg subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to 58 weeks.

Serious adverse events	Placebo	PF-- 04950615 150 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	150 / 1065 (14.08%)	116 / 1063 (10.91%)	
number of deaths (all causes)	9	2	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	2 / 1065 (0.19%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			

subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer	Additional description: This event was gender specific.		
subjects affected / exposed <sup>[1]</sup>	0 / 430 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial adenocarcinoma	Additional description: This event was gender specific.		
subjects affected / exposed <sup>[2]</sup>	0 / 430 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Invasive ductal breast carcinoma			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoma			

subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to spine			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic neoplasm			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer	Additional description: This event was gender specific.		
subjects affected / exposed <sup>[3]</sup>	1 / 430 (0.23%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Schwannoma			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer	Additional description: This event was gender specific.		
subjects affected / exposed <sup>[4]</sup>	3 / 635 (0.47%)	0 / 630 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma recurrent			

subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine cancer	Additional description: This event was gender specific.		
subjects affected / exposed <sup>[5]</sup>	2 / 430 (0.47%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma	Additional description: This event was gender specific.		
subjects affected / exposed <sup>[6]</sup>	0 / 430 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic stenosis			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	4 / 1065 (0.38%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			

subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	2 / 1065 (0.19%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vena cava thrombosis			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Left leg - severe pain, redness, and induration			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			

subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Impaired healing			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oedema peripheral			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	3 / 1065 (0.28%)	7 / 1063 (0.66%)	
occurrences causally related to treatment / all	0 / 3	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral swelling			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Prostatic haemorrhage	Additional description: This event was gender specific.		
subjects affected / exposed <sup>[7]</sup>	0 / 635 (0.00%)	1 / 630 (0.16%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal ulcer	Additional description: This event was gender specific.		

subjects affected / exposed <sup>[8]</sup>	1 / 635 (0.16%)	0 / 630 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal prolapse	Additional description: This event was gender specific.		
subjects affected / exposed <sup>[9]</sup>	1 / 430 (0.23%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	3 / 1065 (0.28%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspiration			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Asthma			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	6 / 1065 (0.56%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			

subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary embolism			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sleep apnoea syndrome			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	1 / 1065 (0.09%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug dependence			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Schizoaffective disorder			



subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood creatinine increased			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure increased			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood urine present			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram change			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			

subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Anastomotic ulcer haemorrhage			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns second degree			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	3 / 1065 (0.28%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			

subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	0 / 1065 (0.00%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional overdose			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laceration			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle injury			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve injury			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			

subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Procedural pain			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft occlusion			

subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft thrombosis			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Bartter's syndrome			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	1 / 1065 (0.09%)	7 / 1063 (0.66%)	
occurrences causally related to treatment / all	0 / 1	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	6 / 1065 (0.56%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	4 / 1065 (0.38%)	8 / 1063 (0.75%)	
occurrences causally related to treatment / all	0 / 4	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	

Aortic valve calcification			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis coronary artery			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriospasm coronary			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	4 / 1065 (0.38%)	4 / 1063 (0.38%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	0 / 1065 (0.00%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			

subjects affected / exposed	0 / 1065 (0.00%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac failure			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	3 / 1065 (0.28%)	4 / 1063 (0.38%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiomyopathy			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiorenal syndrome			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	4 / 1065 (0.38%)	3 / 1063 (0.28%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive heart disease			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coronary artery occlusion			

subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	1 / 1065 (0.09%)	3 / 1063 (0.28%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	2 / 1065 (0.19%)	4 / 1063 (0.38%)	
occurrences causally related to treatment / all	0 / 2	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ventricular extrasystoles			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subvalvular aortic stenosis			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			
subjects affected / exposed	1 / 1065 (0.09%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	1 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Aphasia			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid arteriosclerosis			



subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	3 / 1065 (0.28%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical myelopathy			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolitic stroke			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar infarction			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			

subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental impairment			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	1 / 1065 (0.09%)	3 / 1063 (0.28%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	8 / 1065 (0.75%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 8	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Leukocytosis			

subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	4 / 1065 (0.38%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ulcerative			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Diarrhoea			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer haemorrhage			

subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland calculus			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Volvulus			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	2 / 1065 (0.19%)	3 / 1063 (0.28%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	0 / 1065 (0.00%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal mass			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric obstruction			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	0 / 1065 (0.00%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	3 / 1065 (0.28%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorder			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			

subjects affected / exposed	3 / 1065 (0.28%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metatarsalgia			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck mass			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	1 / 1065 (0.09%)	4 / 1063 (0.38%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyalgia rheumatica			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			



subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
<b>Appendicitis</b>			
subjects affected / exposed	2 / 1065 (0.19%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Appendicitis perforated</b>			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Arthritis bacterial</b>			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bronchitis</b>			
subjects affected / exposed	2 / 1065 (0.19%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cellulitis</b>			
subjects affected / exposed	5 / 1065 (0.47%)	4 / 1063 (0.38%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cellulitis of male external genital organ</b>			
	Additional description: This event was gender specific.		
subjects affected / exposed <sup>[10]</sup>	1 / 635 (0.16%)	0 / 630 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Device related infection</b>			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Diabetic gangrene</b>			

subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	2 / 1065 (0.19%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	1 / 1065 (0.09%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	3 / 1065 (0.28%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			

subjects affected / exposed	10 / 1065 (0.94%)	3 / 1063 (0.28%)	
occurrences causally related to treatment / all	0 / 10	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal abscess	Additional description: This event was gender specific.		
subjects affected / exposed <sup>[11]</sup>	1 / 635 (0.16%)	0 / 630 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sepsis syndrome			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	0 / 1065 (0.00%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sialoadenitis			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			

subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	3 / 1065 (0.28%)	4 / 1063 (0.38%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	2 / 1065 (0.19%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	1 / 1065 (0.09%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	1 / 1065 (0.09%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	1 / 1065 (0.09%)	0 / 1063 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			

subjects affected / exposed	1 / 1065 (0.09%)	2 / 1063 (0.19%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Obesity</b>			
subjects affected / exposed	0 / 1065 (0.00%)	1 / 1063 (0.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

[11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: The event was gender specific event.

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo	PF-- 04950615 150 mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	138 / 1065 (12.96%)	177 / 1063 (16.65%)	
Vascular disorders			
Hypertension			

subjects affected / exposed occurrences (all)	61 / 1065 (5.73%) 66	47 / 1063 (4.42%) 52	
General disorders and administration site conditions Injection site reaction subjects affected / exposed occurrences (all)	23 / 1065 (2.16%) 36	97 / 1063 (9.13%) 329	
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	60 / 1065 (5.63%) 68	50 / 1063 (4.70%) 56	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 July 2014	<ol style="list-style-type: none"><li>1. Treatment duration was reduced from 80 to 52 weeks.</li><li>2. Follow-up period was reduced from 8 to 6 weeks.</li><li>3. Number of SC injection over 52 weeks were updated.</li><li>4. Subjects with lacunar infarct were excluded from the study participation and a hepatitis C serology at the end of treatment was included.</li></ol>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported